Novo Nordisk shares plunge 10% after Alzheimer's drug trial fails to hit key target

Core Insights - Shares of Novo Nordisk fell by as much as 11% following the announcement that a trial for Alzheimer's disease did not meet its primary objective [1] Group 1: Company Performance - The trial evaluated the effectiveness of semaglutide, the active ingredient in Novo's successful diabetes and weight loss medications Ozempic and Wegovy, in slowing the progression of Alzheimer's disease [1]